<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="discussion"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Med</journal-id><journal-id journal-id-type="pmc">Open Med</journal-id><journal-title-group><journal-title>Open Medicine</journal-title></journal-title-group><issn pub-type="epub">1911-2092</issn><publisher><publisher-name>Open Medicine Publications, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21603045</article-id><article-id pub-id-type="pmc">3090117</article-id><article-id pub-id-type="publisher-id">OpenMed-03-e123-130</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Moher</surname><given-names>David</given-names></name><bio><p><bold>David Moher</bold> is at the Ottawa Methods Centre, Ottawa Hospital Research Institute, and the Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.</p></bio></contrib><contrib contrib-type="author"><name><surname>Liberati</surname><given-names>Alessandro</given-names></name><bio><p><bold>Alessandro Liberati</bold> is at the Universit&#x000e0; di Modena e Reggio Emilia, Modena, and the Centro Cochrane Italiano, Istituto Ricerche Farmacologiche Mario Negri, Milan, Italy.</p></bio></contrib><contrib contrib-type="author"><name><surname>Tetzlaff</surname><given-names>Jennifer</given-names></name><bio><p><bold>Jennifer Tetzlaff</bold> is at the Ottawa Methods Centre, Ottawa Hospital Research Institute, Ottawa, Ontario.</p></bio></contrib><contrib contrib-type="author"><name><surname>Altman</surname><given-names>Douglas G</given-names></name><bio><p><bold>Douglas G Altman</bold> is at the Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom.</p></bio></contrib><contrib contrib-type="author"><collab>The PRISMA Group</collab><bio><p>Membership of the PRISMA Group is provided in the Acknowledgements.</p></bio></contrib></contrib-group><author-notes><corresp id="cor1">Correspondence: Dr. David Moher, <email>dmoher@ohri.ca</email></corresp></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>21</day><month>7</month><year>2009</year></pub-date><volume>3</volume><issue>3</issue><fpage>e123</fpage><lpage>e130</lpage><permissions><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/2.5/ca/"><license-p>Open Medicine applies the Creative Commons Attribution Share Alike License, which means that anyone is able to freely copy, download, reprint, reuse, distribute, display or perform this work and that authors retain copyright of their work. Any derivative use of this work must be distributed only under a license identical to this one and must be attributed to the authors. Any of these conditions can be waived with permission from the copyright holder. These conditions do not negate or supersede Fair Use laws in any country.</license-p></license></permissions><self-uri xlink:type="simple" xlink:href="http://www.openmedicine.ca/article/view/285/247">http://www.openmedicine.ca/article/view/285/247</self-uri></article-meta></front><body><p>Systematic reviews and meta-analyses have become increasingly important in health care. Clinicians read them to keep up to date with their field,<xref ref-type="bibr" rid="pmed.1000097-Oxman1">1</xref>,<xref ref-type="bibr" rid="pmed.1000097-Swingler1">2</xref> and they are often used as a starting point for developing clinical practice guidelines. Granting agencies may require a systematic review to ensure there is justification for further research,<xref ref-type="bibr" rid="pmed.1000097-Canadian1">3</xref> and some health care journals are moving in this direction.<xref ref-type="bibr" rid="pmed.1000097-Young1">4</xref> As with all research, the value of a systematic review depends on what was done, what was found, and the clarity of reporting. As with other publications, the reporting quality of systematic reviews varies, limiting readers' ability to assess the strengths and weaknesses of those reviews.</p><p>Several early studies evaluated the quality of review reports. In 1987, Mulrow examined 50 review articles published in 4 leading medical journals in 1985 and 1986 and found that none met all 8 explicit scientific criteria, such as a quality assessment of included studies.<xref ref-type="bibr" rid="pmed.1000097-Mulrow1">5</xref> In 1987, Sacks and colleagues<xref ref-type="bibr" rid="pmed.1000097-Sacks1">6</xref> evaluated the adequacy of reporting of 83 meta-analyses on 23 characteristics in 6 domains. Reporting was generally poor; between 1 and 14 characteristics were adequately reported (mean&#x0200a;=&#x0200a;7.7; standard deviation&#x0200a;=&#x0200a;2.7). A 1996 update of this study found little improvement.<xref ref-type="bibr" rid="pmed.1000097-Sacks2">7</xref></p><p>In 1996, to address the suboptimal reporting of meta-analyses, an international group developed a guidance called the QUOROM Statement (<italic>QU</italic>ality <italic>O</italic>f <italic>R</italic>eporting <italic>O</italic>f <italic>M</italic>eta-analyses), which focused on the reporting of meta-analyses of randomized controlled trials.<xref ref-type="bibr" rid="pmed.1000097-Moher1">8</xref> In this article, we summarize a revision of these guidelines, renamed PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses), which have been updated to address several conceptual and practical advances in the science of systematic reviews (<xref ref-type="fig" rid="box1">Box 1</xref>).</p><sec><title>Terminology</title><p>The terminology used to describe a systematic review and meta-analysis has evolved over time. One reason for changing the name from QUOROM to PRISMA was the desire to encompass both systematic reviews and meta-analyses. We have adopted the definitions used by the Cochrane Collaboration.<xref ref-type="bibr" rid="pmed.1000097-Green1">9</xref> A systematic review is a review of a clearly formulated question that uses systematic and explicit methods to identify, select, and critically appraise relevant research, and to collect and analyze data from the studies that are included in the review. Statistical methods (meta-analysis) may or may not be used to analyze and summarize the results of the included studies. Meta-analysis refers to the use of statistical techniques in a systematic review to integrate the results of included studies.</p></sec><sec><title>Developing the PRISMA Statement</title><p>A 3-day meeting was held in Ottawa, Canada, in June 2005 with 29 participants, including review authors, methodologists, clinicians, medical editors, and a consumer. The objective of the Ottawa meeting was to revise and expand the QUOROM checklist and flow diagram, as needed.</p><p>The executive committee completed the following tasks, prior to the meeting: a systematic review of studies examining the quality of reporting of systematic reviews, and a comprehensive literature search to identify methodological and other articles that might inform the meeting, especially in relation to modifying checklist items. An international survey of review authors, consumers, and groups commissioning or using systematic reviews and meta-analyses was completed, including the International Network of Agencies for Health Technology Assessment (INAHTA) and the Guidelines International Network (GIN). The survey aimed to ascertain views of QUOROM, including the merits of the existing checklist items. The results of these activities were presented during the meeting and are summarized on the <ext-link ext-link-type="uri" xlink:href="http://www.prisma-statement.org/">PRISMA Website</ext-link>.</p><p>Only items deemed essential were retained or added to the checklist. Some additional items are nevertheless desirable, and review authors should include these, if relevant.<xref ref-type="bibr" rid="pmed.1000097-Strech1">10</xref> For example, it is useful to indicate whether the systematic review is an update<xref ref-type="bibr" rid="pmed.1000097-Moher2">11</xref> of a previous review, and to describe any changes in procedures from those described in the original protocol.</p><p>Shortly after the meeting a draft of the PRISMA checklist was circulated to the group, including those invited to the meeting but unable to attend. A disposition file was created containing comments and revisions from each respondent, and the checklist was subsequently revised 11 times. The group approved the checklist, flow diagram, and this summary paper.</p><p>Although no direct evidence was found to support retaining or adding some items, evidence from other domains was believed to be relevant. For example, Item 5 asks authors to provide registration information about the systematic review, including a registration number, if available. Although systematic review registration is not yet widely available,<xref ref-type="bibr" rid="pmed.1000097-University1">12</xref>,<xref ref-type="bibr" rid="pmed.1000097-The1">13</xref> the participating journals of the International Committee of Medical Journal Editors (ICMJE)<xref ref-type="bibr" rid="pmed.1000097-DeAngelis1">14</xref> now require all clinical trials to be registered in an effort to increase transparency and accountability.<xref ref-type="bibr" rid="pmed.1000097-Whittington1">15</xref> Those aspects are also likely to benefit systematic reviewers, possibly reducing the risk of an excessive number of reviews addressing the same question<xref ref-type="bibr" rid="pmed.1000097-Bagshaw1">16</xref>,<xref ref-type="bibr" rid="pmed.1000097-BiondiZoccai1">17</xref> and providing greater transparency when updating systematic reviews.</p></sec><sec><title>The PRISMA Statement</title><p>The PRISMA Statement consists of a 27-item checklist (<xref ref-type="fig" rid="table1">Table 1</xref>; see also <xref ref-type="supplementary-material" rid="texts1">Text S1</xref> for a downloadable template for researchers to re-use) and a 4-phase flow diagram (<xref ref-type="fig" rid="figure1">Figure 1</xref>; see also <xref ref-type="supplementary-material" rid="figures1">Figure S1</xref> for a downloadable template for researchers to re-use). The aim of the PRISMA Statement is to help authors improve the reporting of systematic reviews and meta-analyses. We have focused on randomized trials, but PRISMA can also be used as a basis for reporting systematic reviews of other types of research, particularly evaluations of interventions. PRISMA may also be useful for critical appraisal of published systematic reviews. However, the PRISMA checklist is not a quality assessment instrument to gauge the quality of a systematic review.</p><fig id="box1" position="float"><label>Box 1</label><caption><p>Conceptual issues in the evolution from QUOROM to PRISMA</p></caption><graphic xlink:href="OpenMed-03-e123-g001"/></fig><fig id="figure1" position="float"><label>Figure 1</label><caption><p>Flow of information through the different phases of a systematic review</p></caption><graphic xlink:href="OpenMed-03-e123-g002"/></fig><fig id="table1" position="float"><label>Table 1</label><caption><p>Checklist of items to include when reporting a systematic review or meta-analysis</p></caption><graphic xlink:href="OpenMed-03-e123-g003"/></fig></sec><sec><title>From QUOROM to PRISMA</title><p>The new PRISMA checklist differs in several respects from the QUOROM checklist, and the substantive specific changes are highlighted in <xref ref-type="fig" rid="table2">Table 2</xref>. Generally, the PRISMA checklist &#x0201c;decouples&#x0201d; several items present in the QUOROM checklist and, where applicable, several checklist items are linked to improve consistency across the systematic review report.</p><fig id="table2" position="float"><label>Table 2</label><caption><p>Substantive specific changes between the QUOROM checklist and the PRISMA checklist (a tick indicates the presence of the topic in QUOROM or PRISMA)</p></caption><graphic xlink:href="OpenMed-03-e123-g004"/></fig><p>The flow diagram has also been modified. Before including studies and providing reasons for excluding others, the review team must first search the literature. This search results in records. Once these records have been screened and eligibility criteria applied, a smaller number of articles will remain. The number of included articles might be smaller (or larger) than the number of studies, because articles may report on multiple studies and results from a particular study may be published in several articles. To capture this information, the PRISMA flow diagram now requests information on these phases of the review process.</p></sec><sec><title>Endorsement</title><p>The PRISMA Statement should replace the QUOROM Statement for those journals that have endorsed QUOROM. We hope that other journals will support PRISMA; they can do so by registering on the PRISMA Website. To underscore to authors, and others, the importance of transparent reporting of systematic reviews, we encourage supporting journals to reference the PRISMA Statement and include the PRISMA web address in their Instructions to Authors. We also invite editorial organizations to consider endorsing PRISMA and encourage authors to adhere to its principles.</p></sec><sec><title>The PRISMA Explanation and Elaboration Paper</title><p>In addition to the PRISMA Statement, a supporting Explanation and Elaboration document has been produced<xref ref-type="bibr" rid="pmed.1000097-Liberati1">18</xref> following the style used for other reporting guidelines.<xref ref-type="bibr" rid="pmed.1000097-Altman1">19</xref>-<xref ref-type="bibr" rid="pmed.1000097-Vandenbroucke1">21</xref> The process of completing this document included developing a large database of exemplars to highlight how best to report each checklist item, and identifying a comprehensive evidence base to support the inclusion of each checklist item. The Explanation and Elaboration document was completed after several face-to-face meetings and numerous iterations among several meeting participants, after which it was shared with the whole group for additional revisions and final approval. Finally, the group formed a dissemination subcommittee to help disseminate and implement PRISMA.</p></sec><sec><title>Discussion</title><p>The quality of reporting of systematic reviews is still not optimal.<xref ref-type="bibr" rid="pmed.1000097-Moher3">22</xref>-<xref ref-type="bibr" rid="pmed.1000097-Delaney1">27</xref> In a recent review of 300 systematic reviews, few authors reported assessing possible publication bias,<xref ref-type="bibr" rid="pmed.1000097-Moher3">22</xref> even though there is overwhelming evidence both for its existence<xref ref-type="bibr" rid="pmed.1000097-Dickersin1">28</xref> and its impact on the results of systematic reviews.<xref ref-type="bibr" rid="pmed.1000097-Sutton1">29</xref> Even when the possibility of publication bias is assessed, there is no guarantee that systematic reviewers have assessed or interpreted it appropriately.<xref ref-type="bibr" rid="pmed.1000097-Lau1">30</xref> Although the absence of reporting such an assessment does not necessarily indicate that it was not done, reporting an assessment of possible publication bias is likely to be a marker of the thoroughness of the conduct of the systematic review.</p><p>Several approaches have been developed to conduct systematic reviews on a broader array of questions. For example, systematic reviews are now conducted to investigate cost-effectiveness,<xref ref-type="bibr" rid="pmed.1000097-Ladabaum1">31</xref> diagnostic<xref ref-type="bibr" rid="pmed.1000097-Deeks1">32</xref> or prognostic questions,<xref ref-type="bibr" rid="pmed.1000097-Altman2">33</xref> genetic associations,<xref ref-type="bibr" rid="pmed.1000097-Ioannidis1">34</xref> and policy-making.<xref ref-type="bibr" rid="pmed.1000097-Lavis1">35</xref> The general concepts and topics covered by PRISMA are all relevant to any systematic review, not just those whose objective is to summarize the benefits and harms of a health care intervention. However, some modifications of the checklist items or flow diagram will be necessary in particular circumstances. For example, assessing the risk of bias is a key concept, but the items used to assess this in a diagnostic review are likely to focus on issues such as the spectrum of patients and the verification of disease status, which differ from reviews of interventions. The flow diagram will also need adjustments when reporting individual patient data meta-analysis.<xref ref-type="bibr" rid="pmed.1000097-Stewart1">36</xref></p><p>We have developed an explanatory document<xref ref-type="bibr" rid="pmed.1000097-Liberati1">18</xref> to increase the usefulness of PRISMA. For each checklist item, this document contains an example of good reporting, a rationale for its inclusion, and supporting evidence, including references, whenever possible. We believe this document will also serve as a useful resource for those teaching systematic review methodology. We encourage journals to include reference to the explanatory document in their Instructions to Authors.</p><p>Like any evidence-based endeavour, PRISMA is a living document. To this end we invite readers to comment on the revised version, particularly the new checklist and flow diagram, through the PRISMA website. We will use such information to inform PRISMA's continued development.</p></sec><sec><title/><p><italic>Note:</italic> To encourage dissemination of the PRISMA Statement, this article is freely accessible on the <ext-link ext-link-type="uri" xlink:href="http://www.openmedicine.ca/"><italic>Open Medicine</italic> website</ext-link> and the <ext-link ext-link-type="uri" xlink:href="http://medicine.plosjournals.org/"><italic>PLoS Medicine</italic> website</ext-link> and is also published in the <italic>Annals of Internal Medicine</italic>, <italic>BMJ</italic>, and <italic>Journal of Clinical Epidemiology</italic>. The authors jointly hold the copyright of this article. For details on further use, see the <ext-link ext-link-type="uri" xlink:href="http://www.prisma-statement.org/">PRISMA website</ext-link>. The PRISMA Explanation and Elaboration Paper is <ext-link ext-link-type="uri" xlink:href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1000100">available at the <italic>PLoS Medicine</italic> website</ext-link>.</p></sec><sec sec-type="supplementary-material"><title>Supporting Information</title><supplementary-material content-type="local-data"><media id="figures1" xlink:href="OpenMed-03-e123-s001.pdf" xlink:type="simple" position="anchor" mimetype="application" mime-subtype="pdf"><label>Figure S1</label><caption><p>Flow of information through the different phases of a systematic review (downloadable template document for researchers to re-use)</p></caption></media><media id="texts1" xlink:href="OpenMed-03-e123-s002.pdf" xlink:type="simple" position="anchor" mimetype="application" mime-subtype="pdf"><label>Text S1</label><caption><p>Checklist of items to include when reporting a systematic review or meta-analysis (downloadable template document for researchers to re-use)</p></caption></media></supplementary-material></sec></body><back><ack><p>The following people contributed to the PRISMA Statement: Doug Altman, DSc, Centre for Statistics in Medicine (Oxford, UK); Gerd Antes, PhD, University Hospital Freiburg (Freiburg, Germany); David Atkins, MD, MPH, Health Services Research and Development Service, Veterans Health Administration (Washington, D. C., US); Virginia Barbour, MRCP, DPhil, <italic>PLoS Medicine</italic> (Cambridge, UK); Nick Barrowman, PhD, Children's Hospital of Eastern Ontario (Ottawa, Canada); Jesse A. Berlin, ScD, Johnson &#x00026; Johnson Pharmaceutical Research and Development (Titusville, New Jersey, US); Jocalyn Clark, PhD, <italic>PLoS Medicine</italic> (at the time of writing, <italic>BMJ</italic>, London, UK); Mike Clarke, PhD, UK Cochrane Centre (Oxford, UK) and School of Nursing and Midwifery, Trinity College (Dublin, Ireland); Deborah Cook, MD, Departments of Medicine, Clinical Epidemiology and Biostatistics, McMaster University (Hamilton, Canada); Roberto D'Amico, PhD, Universit&#x000e0; di Modena e Reggio Emilia (Modena, Italy) and Centro Cochrane Italiano, Istituto Ricerche Farmacologiche Mario Negri (Milan, Italy); Jonathan J. Deeks, PhD, University of Birmingham (Birmingham, UK); P. J. Devereaux, MD, PhD, Departments of Medicine, Clinical Epidemiology and Biostatistics, McMaster University (Hamilton, Canada); Kay Dickersin, PhD, Johns Hopkins Bloomberg School of Public Health (Baltimore, Maryland, US); Matthias Egger, MD, Department of Social and Preventive Medicine, University of Bern (Bern, Switzerland); Edzard Ernst, MD, PhD, FRCP, FRCP(Edin), Peninsula Medical School (Exeter, UK); Peter C. G&#x000f8;tzsche, MD, MSc, The Nordic Cochrane Centre (Copenhagen, Denmark); Jeremy Grimshaw, MBChB, PhD, FRCFP, Ottawa Hospital Research Institute (Ottawa, Canada); Gordon Guyatt, MD, Departments of Medicine, Clinical Epidemiology and Biostatistics, McMaster University (Hamilton, Canada); Julian Higgins, PhD, MRC Biostatistics Unit (Cambridge, UK); John P. A. Ioannidis, MD, University of Ioannina Campus (Ioannina, Greece); Jos Kleijnen, MD, PhD, Kleijnen Systematic Reviews Ltd (York, UK) and School for Public Health and Primary Care (CAPHRI), University of Maastricht (Maastricht, Netherlands); Tom Lang, MA, Tom Lang Communications and Training (Davis, California, US); Alessandro Liberati, MD, Universit&#x000e0; di Modena e Reggio Emilia (Modena, Italy) and Centro Cochrane Italiano, Istituto Ricerche Farmacologiche Mario Negri (Milan, Italy); Nicola Magrini, MD, NHS Centre for the Evaluation of the Effectiveness of Health Care &#x02013; CeVEAS (Modena, Italy); David McNamee, PhD, <italic>The Lancet</italic> (London, UK); Lorenzo Moja, MD, MSc, Centro Cochrane Italiano, Istituto Ricerche Farmacologiche Mario Negri (Milan, Italy); David Moher, PhD, Ottawa Methods Centre, Ottawa Hospital Research Institute (Ottawa, Canada); Cynthia Mulrow, MD, MSc, <italic>Annals of Internal Medicine</italic> (Philadelphia, Pennsylvania, US); Maryann Napoli, Center for Medical Consumers (New York, New York, US); Andy Oxman, MD, Norwegian Health Services Research Centre (Oslo, Norway); Ba' Pham, MMath, Toronto Health Economics and Technology Assessment Collaborative (Toronto, Canada) (at the time of the first meeting of the group, GlaxoSmithKline Canada, Mississauga, Canada); Drummond Rennie, MD, FRCP, FACP, University of California San Francisco (San Francisco, California, US); Margaret Sampson, MLIS, Children's Hospital of Eastern Ontario (Ottawa, Canada); Kenneth F. Schulz, PhD, MBA, Family Health International (Durham, North Carolina, US); Paul G. Shekelle, MD, PhD, Southern California Evidence Based Practice Center (Santa Monica, California, US); Jennifer Tetzlaff, BSc, Ottawa Methods Centre, Ottawa Hospital Research Institute (Ottawa, Canada); David Tovey, FRCGP, The Cochrane Library, Cochrane Collaboration (Oxford, UK) (at the time of the first meeting of the group, <italic>BMJ</italic>, London, UK); Peter Tugwell, MD, MSc, FRCPC, Institute of Population Health, University of Ottawa (Ottawa, Canada).</p></ack><fn-group><fn fn-type="con"><p>Contributors: David Moher, Alessandro Liberati, and Douglas Altman wrote the first draft of the paper.  They also participated in regular conference calls, identified the participants, secured funds, planned the meeting, participated in the meeting, and drafted the manuscript. Jennifer Tetzlaff participated in identifying the evidence base for PRISMA, refining the checklist, and drafting the manuscript. All of the authors contributed to the writing of the paper and agreed with the recommendations.</p></fn><fn fn-type="conflict"><p>Competing interests: None declared.</p></fn><fn fn-type="financial-disclosure"><p>Funding source: PRISMA was funded by the Canadian Institutes of Health Research; Universit&#x000e0; di Modena e Reggio Emilia, Italy; Cancer Research UK; Clinical Evidence BMJ Knowledge; the Cochrane Collaboration; and GlaxoSmithKline, Canada. Alessandro Liberati is funded, in part, through grants of the Italian Ministry of University (COFIN - PRIN 2002 prot. 2002061749 and COFIN - PRIN 2006 prot. 2006062298). Douglas G Altman is funded by Cancer Research UK. David Moher is funded by a University of Ottawa Research Chair. None of the sponsors had any involvement in the planning, execution, or write-up of the PRISMA documents. Additionally, no funder played a role in drafting the manuscript.</p></fn></fn-group><ref-list><ref id="pmed.1000097-Oxman1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oxman</surname><given-names>AD</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name></person-group><article-title>Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group</article-title><source>JAMA</source><year>1994</year><volume>272</volume><fpage>1367</fpage><lpage>1371</lpage><pub-id pub-id-type="pmid">7933399</pub-id></element-citation></ref><ref id="pmed.1000097-Swingler1"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swingler</surname><given-names>GH</given-names></name><name><surname>Volmink</surname><given-names>J</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name></person-group><article-title>Number of published systematic reviews and global burden of disease: Database analysis</article-title><source>BMJ</source><year>2003</year><volume>327</volume><fpage>1083</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1136/bmj.327.7423.1083</pub-id><pub-id pub-id-type="pmid">14604930</pub-id></element-citation></ref><ref id="pmed.1000097-Canadian1"><label>3</label><element-citation publication-type="webpage"><collab>Canadian Institutes of Health Research</collab><article-title>Randomized controlled trials registration/application checklist (12/2006)</article-title><year>2006</year><date-in-citation>accessed 19 May 2009</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="http://www.cihr-irsc.gc.ca/e/documents/rct_reg_e.pdf">http://www.cihr-irsc.gc.ca/e/documents/rct_reg_e.pdf</ext-link></comment></element-citation></ref><ref id="pmed.1000097-Young1"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>C</given-names></name><name><surname>Horton</surname><given-names>R</given-names></name></person-group><article-title>Putting clinical trials into context</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>107</fpage><pub-id pub-id-type="pmid">16005318</pub-id></element-citation></ref><ref id="pmed.1000097-Mulrow1"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulrow</surname><given-names>CD</given-names></name></person-group><article-title>The medical review article: State of the science</article-title><source>Ann Intern Med</source><year>1987</year><volume>106</volume><fpage>485</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">3813259</pub-id></element-citation></ref><ref id="pmed.1000097-Sacks1"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacks</surname><given-names>HS</given-names></name><name><surname>Berrier</surname><given-names>J</given-names></name><name><surname>Reitman</surname><given-names>D</given-names></name><name><surname>Ancona-Berk</surname><given-names>VA</given-names></name><name><surname>Chalmers</surname><given-names>TC</given-names></name></person-group><article-title>Meta-analysis of randomized controlled trials</article-title><source>New Engl J Med</source><year>1987</year><volume>316</volume><fpage>450</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">3807986</pub-id></element-citation></ref><ref id="pmed.1000097-Sacks2"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacks</surname><given-names>HS</given-names></name><name><surname>Reitman</surname><given-names>D</given-names></name><name><surname>Pagano</surname><given-names>D</given-names></name><name><surname>Kupelnick</surname><given-names>B</given-names></name></person-group><article-title>Meta-analysis: An update</article-title><source>Mt Sinai J Med</source><year>1996</year><volume>63</volume><fpage>216</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">8692168</pub-id></element-citation></ref><ref id="pmed.1000097-Moher1"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Eastwood</surname><given-names>S</given-names></name><name><surname>Olkin</surname><given-names>I</given-names></name><name><surname>Rennie</surname><given-names>D</given-names></name><name><surname>Stroup</surname><given-names>DF</given-names></name></person-group><collab>PRISMA Group</collab><article-title>Improving the quality of reporting of meta-analysis of randomized controlled trials: The QUOROM statement</article-title><source>Lancet</source><year>1994</year><volume>354</volume><fpage>1896</fpage><lpage>1900</lpage><pub-id pub-id-type="pmid">10584742</pub-id></element-citation></ref><ref id="pmed.1000097-Green1"><label>9</label><element-citation publication-type="webpage"><person-group person-group-type="editor"><name><surname>Green</surname><given-names>S</given-names></name><name><surname>Higgins</surname><given-names>J</given-names></name></person-group><article-title>Glossary</article-title><source>Cochrane handbook for systematic reviews of interventions 4.2.5. The Cochrane Collaboration</source><year>2005</year><date-in-citation>accessed 19 May 2009</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="http://www.cochrane.org/resources/glossary.htm">http://www.cochrane.org/resources/glossary.htm</ext-link></comment></element-citation></ref><ref id="pmed.1000097-Strech1"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strech</surname><given-names>D</given-names></name><name><surname>Tilburt</surname><given-names>J</given-names></name></person-group><article-title>Value judgments in the analysis and synthesis of evidence</article-title><source>J Clin Epidemiol</source><year>2008</year><volume>61</volume><fpage>521</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2008.01.001</pub-id><pub-id pub-id-type="pmid">18471654</pub-id></element-citation></ref><ref id="pmed.1000097-Moher2"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Tsertsvadze</surname><given-names>A</given-names></name></person-group><article-title>Systematic reviews: When is an update an update?</article-title><source>Lancet</source><year>2006</year><volume>367</volume><fpage>881</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">16546523</pub-id></element-citation></ref><ref id="pmed.1000097-University1"><label>12</label><element-citation publication-type="webpage"><collab>University of York</collab><article-title>Centre for Reviews and Dissemination</article-title><year>2009</year><date-in-citation>accessed 19 May 2009</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="http://www.york.ac.uk/inst/crd/">http://www.york.ac.uk/inst/crd/</ext-link></comment></element-citation></ref><ref id="pmed.1000097-The1"><label>13</label><element-citation publication-type="webpage"><collab>The Joanna Briggs Institute</collab><article-title>Protocols &#x00026; work in progress</article-title><year>2008</year><date-in-citation>accessed 19 May 2009</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="http://www.joannabriggs.edu.au/pubs/systematic_reviews_prot.php">http://www.joannabriggs.edu.au/pubs/systematic_reviews_prot.php</ext-link></comment></element-citation></ref><ref id="pmed.1000097-DeAngelis1"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Angelis</surname><given-names>Catherine</given-names></name><name><surname>Drazen</surname><given-names>Jeffrey M</given-names></name><name><surname>Frizelle</surname><given-names>Frank A</given-names></name><name><surname>Haug</surname><given-names>Charlotte</given-names></name><name><surname>Hoey</surname><given-names>John</given-names></name><name><surname>Horton</surname><given-names>Richard</given-names></name><name><surname>Kotzin</surname><given-names>Sheldon</given-names></name><name><surname>Laine</surname><given-names>Christine</given-names></name><name><surname>Marusic</surname><given-names>Ana</given-names></name><name><surname>Overbeke</surname><given-names>A John P M</given-names></name><name><surname>Schroeder</surname><given-names>Torben V</given-names></name><name><surname>Sox</surname><given-names>Hal C</given-names></name><name><surname>Van Der Weyden</surname><given-names>Martin B</given-names></name></person-group><collab>International Committee of Medical Journal Editors</collab><article-title>Clinical trial registration: A statement from the International Committee of Medical Journal Editors</article-title><source>CMAJ</source><year>2004</year><volume>171</volume><fpage>606</fpage><lpage>607</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.cmaj.ca/cgi/pmidlookup?view=long&#x00026;pmid=15367465">http://www.cmaj.ca/cgi/pmidlookup?view=long&#x00026;pmid=15367465</ext-link></comment><pub-id pub-id-type="doi">10.1503/cmaj.1041281</pub-id><pub-id pub-id-type="pmid">15367465</pub-id></element-citation></ref><ref id="pmed.1000097-Whittington1"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittington</surname><given-names>CJ</given-names></name><name><surname>Kendall</surname><given-names>T</given-names></name><name><surname>Fonagy</surname><given-names>P</given-names></name><name><surname>Cottrell</surname><given-names>D</given-names></name><name><surname>Cotgrove</surname><given-names>A</given-names></name><name><surname>Boddington</surname><given-names>E</given-names></name></person-group><article-title>Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>1341</fpage><lpage>1345</lpage><pub-id pub-id-type="pmid">15110490</pub-id></element-citation></ref><ref id="pmed.1000097-Bagshaw1"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagshaw</surname><given-names>SM</given-names></name><name><surname>McAlister</surname><given-names>FA</given-names></name><name><surname>Manns</surname><given-names>BJ</given-names></name><name><surname>Ghali</surname><given-names>WA</given-names></name></person-group><article-title>Acetylcysteine in the prevention of contrast-induced nephropathy: A case study of the pitfalls in the evolution of evidence</article-title><source>Arch Intern Med</source><year>2006</year><volume>166</volume><fpage>161</fpage><lpage>166</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://archinte.ama-assn.org/cgi/pmidlookup?view=long&#x00026;pmid=16432083">http://archinte.ama-assn.org/cgi/pmidlookup?view=long&#x00026;pmid=16432083</ext-link></comment><pub-id pub-id-type="doi">10.1001/archinte.166.2.161</pub-id><pub-id pub-id-type="pmid">16432083</pub-id></element-citation></ref><ref id="pmed.1000097-BiondiZoccai1"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biondi-Zoccai</surname><given-names>GG</given-names></name><name><surname>Lotrionte</surname><given-names>M</given-names></name><name><surname>Abbate</surname><given-names>A</given-names></name><name><surname>Testa</surname><given-names>L</given-names></name><name><surname>Remigi</surname><given-names>E</given-names></name><name><surname>Burzotta</surname><given-names>F</given-names></name></person-group><article-title>Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: Case study</article-title><source>BMJ</source><year>2006</year><volume>332</volume><fpage>202</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">16415336</pub-id></element-citation></ref><ref id="pmed.1000097-Liberati1"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><name><surname>Mulrow</surname><given-names>C</given-names></name><name><surname>G&#x000f8;tzsche</surname><given-names>P</given-names></name></person-group><collab>PRISMA Group</collab><article-title>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration</article-title><source>PLoS Med</source><year>2009</year><volume>6</volume><fpage>e1000100</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1000100</pub-id><pub-id pub-id-type="pmid">19621070</pub-id></element-citation></ref><ref id="pmed.1000097-Altman1"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Schulz</surname><given-names>KR</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Davidoff</surname><given-names>F</given-names></name><name><surname>Elbourne</surname><given-names>D</given-names></name></person-group><collab>CONSORT group</collab><article-title>The revised CONSORT statement for reporting randomized trials: Explanation and elaboration</article-title><source>Ann Intern Med</source><year>2001</year><volume>134</volume><fpage>663</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">11304107</pub-id></element-citation></ref><ref id="pmed.1000097-Bossuyt1"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bossuyt</surname><given-names>PM</given-names></name><name><surname>Reitsma</surname><given-names>JB</given-names></name><name><surname>Bruns</surname><given-names>DE</given-names></name><name><surname>Gatsonis</surname><given-names>CA</given-names></name><name><surname>Glasziou</surname><given-names>PP</given-names></name></person-group><collab>STARD group</collab><article-title>Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD explanation and elaboration</article-title><source>Ann Intern Med</source><year>2003</year><volume>138</volume><fpage>W1</fpage><lpage>W12</lpage><pub-id pub-id-type="pmid">12513067</pub-id></element-citation></ref><ref id="pmed.1000097-Vandenbroucke1"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandenbroucke</surname><given-names>JP</given-names></name><name><surname>von Elm</surname><given-names>E</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>G&#x000f8;tzsche</surname><given-names>PC</given-names></name><name><surname>Mulrow</surname><given-names>CD</given-names></name></person-group><collab>STROBE initiative</collab><article-title>Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration</article-title><source>Ann Intern Med</source><year>2007</year><volume>147</volume><fpage>W163</fpage><lpage>W194</lpage><pub-id pub-id-type="pmid">17938389</pub-id></element-citation></ref><ref id="pmed.1000097-Moher3"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><name><surname>Tricco</surname><given-names>AC</given-names></name><name><surname>Sampson</surname><given-names>M</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Epidemiology and reporting characteristics of systematic reviews</article-title><source>PLoS Med</source><year>2007</year><volume>4</volume><fpage>e78</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0040078</pub-id><pub-id pub-id-type="pmid">17388659</pub-id></element-citation></ref><ref id="pmed.1000097-Bhandari1"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhandari</surname><given-names>M</given-names></name><name><surname>Morrow</surname><given-names>F</given-names></name><name><surname>Kulkarni</surname><given-names>AV</given-names></name><name><surname>Tornetta</surname><given-names>P</given-names></name></person-group><article-title>Meta-analyses in orthopaedic surgery: A systematic review of their methodologies</article-title><source>J Bone Joint Surg Am</source><year>2001</year><volume>83-A</volume><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">11205853</pub-id></element-citation></ref><ref id="pmed.1000097-Kelly1"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>KD</given-names></name><name><surname>Travers</surname><given-names>A</given-names></name><name><surname>Dorgan</surname><given-names>M</given-names></name><name><surname>Slater</surname><given-names>L</given-names></name><name><surname>Rowe</surname><given-names>BH</given-names></name></person-group><article-title>Evaluating the quality of systematic reviews in the emergency medicine literature</article-title><source>Ann Emerg Med</source><year>2001</year><volume>38</volume><fpage>518</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">11679863</pub-id></element-citation></ref><ref id="pmed.1000097-Richards1"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>D</given-names></name></person-group><article-title>The quality of systematic reviews in dentistry</article-title><source>Evid Based Dent</source><year>2004</year><volume>5</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1038/sj.ebd.6400242</pub-id><pub-id pub-id-type="pmid">15238972</pub-id></element-citation></ref><ref id="pmed.1000097-Choi1"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>PT</given-names></name><name><surname>Halpern</surname><given-names>SH</given-names></name><name><surname>Malik</surname><given-names>N</given-names></name><name><surname>Jadad</surname><given-names>AR</given-names></name><name><surname>Tramer</surname><given-names>MR</given-names></name></person-group><article-title>Examining the evidence in anesthesia literature: A critical appraisal of systematic reviews</article-title><source>Anesth Analg</source><year>2001</year><volume>92</volume><fpage>700</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">11226105</pub-id></element-citation></ref><ref id="pmed.1000097-Delaney1"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delaney</surname><given-names>A</given-names></name><name><surname>Bagshaw</surname><given-names>SM</given-names></name><name><surname>Ferland</surname><given-names>A</given-names></name><name><surname>Manns</surname><given-names>B</given-names></name><name><surname>Laupland</surname><given-names>KB</given-names></name></person-group><article-title>A systematic evaluation of the quality of meta-analyses in the critical care literature</article-title><source>Crit Care</source><year>2005</year><volume>9</volume><fpage>R575</fpage><lpage>R582</lpage><pub-id pub-id-type="pmid">16277721</pub-id></element-citation></ref><ref id="pmed.1000097-Dickersin1"><label>28</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Dickersin</surname><given-names>K</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Rothstein</surname><given-names>HR</given-names></name><name><surname>Sutton</surname><given-names>AJ</given-names></name><name><surname>Borenstein</surname><given-names>M</given-names></name></person-group><article-title>Publication bias: Recognizing the problem, understanding its origins and scope, and preventing harm</article-title><source>Publication bias in meta-analysis-Prevention, assessment and adjustments</source><year>2005</year><publisher-loc>Chichester (UK)</publisher-loc><publisher-name>John Wiley &#x00026; Sons</publisher-name><fpage>11</fpage><lpage>33</lpage></element-citation></ref><ref id="pmed.1000097-Sutton1"><label>29</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sutton</surname><given-names>AJ</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Rothstein</surname><given-names>HR</given-names></name><name><surname>Sutton</surname><given-names>AJ</given-names></name><name><surname>Borenstein</surname><given-names>M</given-names></name></person-group><article-title>Evidence concerning the consequences of publication and related biases</article-title><source>Publication bias in meta-analysis &#x02014; Prevention, assessment and adjustments</source><year>2005</year><publisher-loc>Chichester (UK)</publisher-loc><publisher-name>John Wiley &#x00026; Sons</publisher-name><fpage>175</fpage><lpage>192</lpage></element-citation></ref><ref id="pmed.1000097-Lau1"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>J</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Terrin</surname><given-names>N</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name><name><surname>Olkin</surname><given-names>I</given-names></name></person-group><article-title>The case of the misleading funnel plot</article-title><source>BMJ</source><year>2006</year><volume>333</volume><fpage>597</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">16974018</pub-id></element-citation></ref><ref id="pmed.1000097-Ladabaum1"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ladabaum</surname><given-names>U</given-names></name><name><surname>Chopra</surname><given-names>CL</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Scheiman</surname><given-names>JM</given-names></name><name><surname>Chernew</surname><given-names>ME</given-names></name></person-group><article-title>Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: A cost-effectiveness analysis</article-title><source>Ann Intern Med</source><year>2001</year><volume>135</volume><fpage>769</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">11694102</pub-id></element-citation></ref><ref id="pmed.1000097-Deeks1"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>JJ</given-names></name></person-group><article-title>Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests</article-title><source>BMJ</source><year>2001</year><volume>323</volume><fpage>157</fpage><lpage>162</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x00026;pubmedid=11463691">http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&#x00026;pubmedid=11463691</ext-link></comment><pub-id pub-id-type="pmid">11463691</pub-id></element-citation></ref><ref id="pmed.1000097-Altman2"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Systematic reviews of evaluations of prognostic variables</article-title><source>BMJ</source><year>2001</year><volume>323</volume><fpage>224</fpage><lpage>228</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://bmj.com/cgi/pmidlookup?view=long&#x00026;pmid=11473921">http://bmj.com/cgi/pmidlookup?view=long&#x00026;pmid=11473921</ext-link></comment><pub-id pub-id-type="pmid">11473921</pub-id></element-citation></ref><ref id="pmed.1000097-Ioannidis1"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Ntzani</surname><given-names>EE</given-names></name><name><surname>Trikalinos</surname><given-names>TA</given-names></name><name><surname>Contopoulos-Ioannidis</surname><given-names>DG</given-names></name></person-group><article-title>Replication validity of genetic association studies</article-title><source>Nat Genet</source><year>2001</year><volume>29</volume><fpage>306</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1038/ng749</pub-id><pub-id pub-id-type="pmid">11600885</pub-id></element-citation></ref><ref id="pmed.1000097-Lavis1"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavis</surname><given-names>J</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Oxman</surname><given-names>A</given-names></name><name><surname>Denis</surname><given-names>J</given-names></name><name><surname>Golden-Biddle</surname><given-names>K</given-names></name></person-group><article-title>Towards systematic reviews that inform health care management and policy-making</article-title><source>J Health Serv Res Policy</source><year>2005</year><volume>10</volume><fpage>35</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1258/1355819054308549</pub-id><pub-id pub-id-type="pmid">16053582</pub-id></element-citation></ref><ref id="pmed.1000097-Stewart1"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>LA</given-names></name><name><surname>Clarke</surname><given-names>MJ</given-names></name></person-group><article-title>Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group</article-title><source>Stat Med</source><year>1995</year><volume>14</volume><fpage>2057</fpage><lpage>2079</lpage><pub-id pub-id-type="pmid">8552887</pub-id></element-citation></ref><ref id="pmed.1000097-Moja1"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moja</surname><given-names>LP</given-names></name><name><surname>Telaro</surname><given-names>E</given-names></name><name><surname>D'Amico</surname><given-names>R</given-names></name><name><surname>Moschetti</surname><given-names>I</given-names></name><name><surname>Coe</surname><given-names>L</given-names></name></person-group><article-title>Assessment of methodological quality of primary studies by systematic reviews: Results of the metaquality cross sectional study</article-title><source>BMJ</source><year>2005</year><volume>330</volume><fpage>1053</fpage><lpage>1055</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://bmj.com/cgi/pmidlookup?view=long&#x00026;pmid=15817526">http://bmj.com/cgi/pmidlookup?view=long&#x00026;pmid=15817526</ext-link></comment><pub-id pub-id-type="doi">10.1136/bmj.38414.515938.8F</pub-id><pub-id pub-id-type="pmid">15817526</pub-id></element-citation></ref><ref id="pmed.1000097-Guyatt1"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Oxman</surname><given-names>AD</given-names></name><name><surname>Vist</surname><given-names>GE</given-names></name><name><surname>Kunz</surname><given-names>R</given-names></name><name><surname>Falck-Ytter</surname><given-names>Y</given-names></name></person-group><collab>GRADE Working Group</collab><article-title>GRADE: An emerging consensus on rating quality of evidence and strength of recommendations</article-title><source>BMJ</source><year>2008</year><volume>336</volume><fpage>924</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1136/bmj.39489.470347.AD</pub-id><pub-id pub-id-type="pmid">18436948</pub-id></element-citation></ref><ref id="pmed.1000097-Schunemann1"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schunemann</surname><given-names>HJ</given-names></name><name><surname>Jaeschke</surname><given-names>R</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Bria</surname><given-names>WF</given-names></name><name><surname>El-Solh</surname><given-names>AA</given-names></name></person-group><collab>ATS Documents Development and Implementation Committee</collab><article-title>An official ATS statement: Grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>174</volume><fpage>605</fpage><lpage>614</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://ajrccm.atsjournals.org/cgi/pmidlookup?view=long&#x00026;pmid=16931644">http://ajrccm.atsjournals.org/cgi/pmidlookup?view=long&#x00026;pmid=16931644</ext-link></comment><pub-id pub-id-type="doi">10.1164/rccm.200602-197ST</pub-id><pub-id pub-id-type="pmid">16931644</pub-id></element-citation></ref><ref id="pmed.1000097-Chan1"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>AW</given-names></name><name><surname>Hrobjartsson</surname><given-names>A</given-names></name><name><surname>Haahr</surname><given-names>MT</given-names></name><name><surname>G&#x000f8;tzsche</surname><given-names>PC</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Empirical evidence for selective reporting of outcomes in randomized trials: Comparison of protocols to published articles</article-title><source>JAMA</source><year>2004</year><volume>291</volume><fpage>2457</fpage><lpage>2465</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://jama.ama-assn.org/cgi/pmidlookup?view=long&#x00026;pmid=15161896">http://jama.ama-assn.org/cgi/pmidlookup?view=long&#x00026;pmid=15161896</ext-link></comment><pub-id pub-id-type="doi">10.1001/jama.291.20.2457</pub-id><pub-id pub-id-type="pmid">15161896</pub-id></element-citation></ref><ref id="pmed.1000097-Chan2"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>AW</given-names></name><name><surname>Krleza-Jeric</surname><given-names>K</given-names></name><name><surname>Schmid</surname><given-names>I</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research</article-title><source>CMAJ</source><year>2004</year><volume>171</volume><fpage>735</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">15451835</pub-id></element-citation></ref><ref id="pmed.1000097-Silagy1"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silagy</surname><given-names>CA</given-names></name><name><surname>Middleton</surname><given-names>P</given-names></name><name><surname>Hopewell</surname><given-names>S</given-names></name></person-group><article-title>Publishing protocols of systematic reviews: Comparing what was done to what was planned</article-title><source>JAMA</source><year>2002</year><volume>287</volume><fpage>2831</fpage><lpage>2834</lpage><comment><ext-link ext-link-type="uri" xlink:href="http://jama.ama-assn.org/cgi/pmidlookup?view=long&#x00026;pmid=12038926">http://jama.ama-assn.org/cgi/pmidlookup?view=long&#x00026;pmid=12038926</ext-link></comment><pub-id pub-id-type="pmid">12038926</pub-id></element-citation></ref></ref-list></back></article>